KR101474188B1 - 질병의 발병률 및 지속기간의 감소에 사용하기 위한 프로바이오틱 - Google Patents

질병의 발병률 및 지속기간의 감소에 사용하기 위한 프로바이오틱 Download PDF

Info

Publication number
KR101474188B1
KR101474188B1 KR1020137030884A KR20137030884A KR101474188B1 KR 101474188 B1 KR101474188 B1 KR 101474188B1 KR 1020137030884 A KR1020137030884 A KR 1020137030884A KR 20137030884 A KR20137030884 A KR 20137030884A KR 101474188 B1 KR101474188 B1 KR 101474188B1
Authority
KR
South Korea
Prior art keywords
child
symptoms
culture
respiratory
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020137030884A
Other languages
English (en)
Korean (ko)
Other versions
KR20140002069A (ko
Inventor
그레고리 레이어
아서 오위핸드
Original Assignee
듀폰 뉴트리션 바이오사이언시즈 에이피에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39268947&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101474188(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 듀폰 뉴트리션 바이오사이언시즈 에이피에스 filed Critical 듀폰 뉴트리션 바이오사이언시즈 에이피에스
Publication of KR20140002069A publication Critical patent/KR20140002069A/ko
Application granted granted Critical
Publication of KR101474188B1 publication Critical patent/KR101474188B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Otolaryngology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020137030884A 2006-10-02 2007-09-14 질병의 발병률 및 지속기간의 감소에 사용하기 위한 프로바이오틱 Active KR101474188B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84866206P 2006-10-02 2006-10-02
US60/848,662 2006-10-02
PCT/US2007/020033 WO2008042101A2 (en) 2006-10-02 2007-09-14 Probiotics for use in reducing the incidence and duration of illness

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR20097006213A Division KR101485200B1 (ko) 2006-10-02 2007-09-14 질병의 발병률 및 지속기간의 감소에 사용하기 위한 프로바이오틱

Publications (2)

Publication Number Publication Date
KR20140002069A KR20140002069A (ko) 2014-01-07
KR101474188B1 true KR101474188B1 (ko) 2014-12-17

Family

ID=39268947

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020137030884A Active KR101474188B1 (ko) 2006-10-02 2007-09-14 질병의 발병률 및 지속기간의 감소에 사용하기 위한 프로바이오틱
KR20097006213A Active KR101485200B1 (ko) 2006-10-02 2007-09-14 질병의 발병률 및 지속기간의 감소에 사용하기 위한 프로바이오틱

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR20097006213A Active KR101485200B1 (ko) 2006-10-02 2007-09-14 질병의 발병률 및 지속기간의 감소에 사용하기 위한 프로바이오틱

Country Status (13)

Country Link
US (5) US20100040579A1 (enExample)
EP (2) EP2839836B2 (enExample)
JP (3) JP5896589B2 (enExample)
KR (2) KR101474188B1 (enExample)
CN (1) CN101528244B (enExample)
AU (1) AU2007302715B2 (enExample)
BR (1) BRPI0719787A2 (enExample)
DK (2) DK2839836T4 (enExample)
ES (2) ES2547480T3 (enExample)
FI (1) FI2839836T4 (enExample)
MX (1) MX2009003260A (enExample)
PL (2) PL2839836T5 (enExample)
WO (1) WO2008042101A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2509151B1 (en) 2009-12-02 2014-08-20 KMW Inc. Device selection structure
JP5885287B2 (ja) * 2010-09-02 2016-03-15 アサヒカルピスウェルネス株式会社 インフルエンザの予防および／または治療剤
KR101806435B1 (ko) 2010-10-15 2017-12-07 시에이치알. 한센 에이/에스 면역보강제
EP2455092A1 (en) 2010-11-11 2012-05-23 Nestec S.A. Non-replicating probiotic micro-organisms protect against upper respiratory tract infections
EP2455093A1 (en) 2010-11-11 2012-05-23 Nestec S.A. Non-replicating probiotic bacteria and prevention or treatment of infections in children
WO2015071389A1 (en) 2013-11-15 2015-05-21 Nestec S.A. Compositions for use in the prevention or treatment of urt infections in infants or young children at risk
CN103798392B (zh) * 2014-03-07 2015-12-30 内蒙古伊利实业集团股份有限公司 具有缓解咽喉部炎症功效的益生菌食品组合物及食品
AU2016227595B2 (en) 2015-03-05 2020-08-27 Société des Produits Nestlé S.A. Compositions for use in the prevention or treatment of otitis or bronchitis in infants or young children
WO2020170982A1 (ja) 2019-02-21 2020-08-27 オリンパス株式会社 フローラ治療用留置体、フローラ治療法
WO2021062250A1 (en) 2019-09-25 2021-04-01 Tall Goods, Llc Methods for producing probiotics fortified avian eggs and egg products and formulations thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072794A1 (en) 2002-10-11 2004-04-15 Wyeth Nutritional formulations containing synbiotic substances
WO2006054135A1 (en) 2004-11-16 2006-05-26 Anidral S.R.L. Probiotic bacteria based composition and use thereof in the prevention and/or treatment of respiratory pathologies and/or infections and in the improvement of the intestinal functionality

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4007A (en) * 1845-04-22 Improvement in separating tannin and coloring-matter in quercitron-bark
AU5113798A (en) * 1996-11-29 1998-06-22 Bio K & International Inc. Lactic ferment comprising a particular strain of (lactobacillus acidophilus) and use thereof
JP4212838B2 (ja) * 2002-06-26 2009-01-21 カルピス株式会社 抗アレルギー剤
RU2407784C2 (ru) * 2003-12-17 2010-12-27 Н.В. Нютрисиа Пробиотический штамм lactobacillus casei, продуцирующий молочную кислоту, применение штамма для приготовления питательной композиции для лечения или профилактики легочной дисфункции, питательная композиция и способ ее получения, лекарственное средство для лечения или профилактики хронической обструктивной болезни легких у субъекта и применение штамма для приготовления лекарственного средства, контейнер
DE102004026706A1 (de) * 2004-05-28 2005-12-15 Merck Patent Gmbh Orale Darreichungsform enthaltend probiotische Bakterien
CA2470090A1 (fr) * 2004-06-18 2005-12-18 Bio-K Plus International Inc. Bacteries lactiques et leurs usages dans la prevention de diarrhee associee aux antibiotiques
US7862808B2 (en) 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
US7981412B2 (en) * 2005-02-15 2011-07-19 Gorbach Sherwood L Food containing a probiotic and an isolated β-glucan and methods of use thereof
US20070020249A1 (en) * 2005-04-29 2007-01-25 Downs Bernard W Compositions for prevention and treatement of symptoms of gastrointestinal distress
EP1951273B1 (en) 2005-10-06 2014-02-12 Probi Ab Use of lactobacillus for treatment of autoimmune diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072794A1 (en) 2002-10-11 2004-04-15 Wyeth Nutritional formulations containing synbiotic substances
WO2006054135A1 (en) 2004-11-16 2006-05-26 Anidral S.R.L. Probiotic bacteria based composition and use thereof in the prevention and/or treatment of respiratory pathologies and/or infections and in the improvement of the intestinal functionality

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FEMS Microbiology Ecology, 2005, 52, Page. 145-152
J. Dairy Sci., 1999, 82(4), Pages. 649-660

Also Published As

Publication number Publication date
US20140356329A1 (en) 2014-12-04
EP2839836B1 (en) 2017-08-30
ES2547480T3 (es) 2015-10-06
EP2839836B2 (en) 2024-06-26
MX2009003260A (es) 2009-05-11
CN101528244B (zh) 2012-01-11
CN101528244A (zh) 2009-09-09
KR20140002069A (ko) 2014-01-07
ES2650375T3 (es) 2018-01-18
US20200316145A1 (en) 2020-10-08
JP5896589B2 (ja) 2016-03-30
BRPI0719787A2 (pt) 2014-11-25
US20180000875A1 (en) 2018-01-04
JP2014058558A (ja) 2014-04-03
KR20090063222A (ko) 2009-06-17
PL2839836T5 (pl) 2025-11-17
PL2068899T3 (pl) 2015-12-31
EP2068899A2 (en) 2009-06-17
DK2839836T3 (en) 2017-12-04
KR101485200B1 (ko) 2015-01-26
EP2839836A1 (en) 2015-02-25
US20100040579A1 (en) 2010-02-18
JP2016128478A (ja) 2016-07-14
WO2008042101A2 (en) 2008-04-10
AU2007302715A1 (en) 2008-04-10
JP2010505824A (ja) 2010-02-25
WO2008042101A3 (en) 2009-04-09
EP2068899B1 (en) 2015-07-01
AU2007302715B2 (en) 2013-01-31
FI2839836T4 (fi) 2024-08-26
DK2839836T4 (da) 2024-08-26
PL2839836T3 (pl) 2018-02-28
US20230256037A1 (en) 2023-08-17
DK2068899T3 (da) 2015-09-28
ES2650375T5 (en) 2025-02-03

Similar Documents

Publication Publication Date Title
US20230256037A1 (en) Probiotics for use in reducing the incidence and duration of illness
Guillemard et al. Consumption of a fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 reduces the duration of respiratory infections in the elderly in a randomised controlled trial
TWI374745B (en) Use of a combination of bifidobacterium lactis bb-12 and lactobacillus rhamnosus gg for preventing or treating respiratory infections and acute otitis media in infants
Fujita et al. Decreased duration of acute upper respiratory tract infections with daily intake of fermented milk: a multicenter, double-blinded, randomized comparative study in users of day care facilities for the elderly population
Garland et al. The ProPrems trial: investigating the effects of probiotics on late onset sepsis in very preterm infants
ES2399775T3 (es) Composiciones farmacéuticas que comprenden L. acidophilus y bifidobacterium lactis para el uso en el tratamiento de un trastorno intestinal funcional
Hoy-Schulz et al. Safety and acceptability of Lactobacillus reuteri DSM 17938 and Bifidobacterium longum subspecies infantis 35624 in Bangladeshi infants: a phase I randomized clinical trial
Banerjee et al. Importance of probiotics in human health
AU2013201783B2 (en) Probiotics for use in reducing the incidence and duration of illness
Lehtoranta Probiotics and immune modulation: reducing risk for cold and flu
Johnson Impact of medical drugs, commonly administered to the elderly, on viability and functionality of commercially available probiotic supplements
Varshney An analysis of probiotics
Tang et al. Effect of yogurt fermented with Lactobacillus delbrueckii ssp. bulgaricus OLL1073R-1 and Streptococcus thermophilus OLS3059 on the physical condition of elementary school students: a large-scale, non-randomized, open-labelled, crossover trial
US20160354419A9 (en) Probiotics for use in relieving symptoms associated with gastrointestinal disorders
Ogwang Prevalence and factors associated pneumonia among children below five years attending pediatric ward at Bushenyi health center IV, Bushenyi district.
Peate A Pilot Study to Determine the Effectiveness of Probiotic Use in Elderly Patients with Antibiotic-Associated Diarrhea
Desland et al. Commonly Asked Questions about Probiotics and the Potential Benefits for Your Health: MB005/MB005, 12/2011
Udani et al. Probiotics for the Treatment of Helicobacter pylori

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20171117

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20181115

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 12